Table 2 Risk of hospitalized infections and malignancies associated with abatacept in RA by line of treatment
Outcomes | Using inverse probability of treatment weights | |||||
|---|---|---|---|---|---|---|
Abatacept vs other bDMARDs | Abatacept vs csDMARDs | |||||
No. of cases/no. of patients* | Unadjusted HR (95% CI) | Adjusted HR†(95% CI) | No. of cases/no. of patients* | Unadjusted HR (95% CI) | Adjusted HR†(95% CI) | |
Hospitalized infections | ||||||
 Overall | 37/1099 vs 25/3138 | 0.39 (0.17, 0.87) | 0.37 (0.18, 0.75) | 37/1099 vs 20/1103 | 0.52 (0.20, 1.39) | 0.31 (0.09, 1.05) |
 First-line | 1/171 vs 13/1191 | NR | NR | 1/171 vs 15/304 | NR | NR |
 Second-line | 15/409 vs 7/1132 | 0.49 (0.23, 1.03) | 0.42 (0.18, 0.97) | 15/409 vs 4/119 | 0.99 (0.26, 3.76) | NR |
 Third- or greater line | 21/659 vs 5/1192 | 0.76 (0.42, 1.38) | 0.64 (0.35, 1.15) | 21/659 vs 1/50 | 0.47 (0.13, 1.68) | 0.42 (0.09, 2.10) |
Malignancies* | ||||||
 Overall | 22/1099 vs 27/3138 | 2.32 (0.84, 6.44) | 1.89 (0.93, 3.84) | 22/1099 vs 24/1103 | 0.77 (0.29, 2.06) | 0.93 (0.20, 4.27) |
 First-line | 3/171 vs 14/1191 | NR | NR | 3/171 vs 17/304 | 0.75 (0.09, 6.13) | 0.36 (0.03, 3.83) |
 Second-line | 6/409 vs 8/1132 | 4.61 (0.98, 21.7) | NR | 6/409 vs 6/119 | NR | NR |
 Third- or greater line | 13/659 vs 5/1192 | 0.35 (0.04, 3.08) | 1.34 (0.39, 4.57) | 13/659 vs 1/50 | 0.61 (0.06, 5.75) | NR |
Non-melanoma skin cancers | ||||||
 Overall | 37/1099 vs 25/3138 | 1.26 (0.69, 2.29) | 1.10 (0.57, 2.11) | 37/1099 vs 20/1103 | 0.90 (0.33, 2.46) | 1.05 (0.22, 4.98) |
 First-line | 1/171 vs 13/1191 | NR | NR | 1/171 vs 15/304 | 0.88 (0.10, 7.37) | 0.62 (0.05, 7.28) |
 Second-line | 15/409 vs 7/1132 | 4.08 (0.80, 20.67) | NR | 15/409 vs 4/119 | NR | NR |
 Third- or greater line | 21/659 vs 5/1192 | 0.35 (0.0, 3.08) | 1.34 (0.39, 4.57) | 21/659 vs 1/50 | 0.61 (0.06, 5.75) | NR |